INTRODUCTION {#s1}
============

Prostate cancer (PCa) is the leading malignancy in developed nations and ranks second in cancer deaths worldwide \[[@R1], [@R2]\]. Its incidence has increased rapidly in China \[[@R3], [@R4]\], with an estimated incidence of 1 in 10000 in 2010 \[[@R5]\]. Although environmental and genetic factors are associated with PCa carcinogenesis, the actual causes are unknown. Published genome-wide association studies (GWAS) identified 40 single nucleotide polymorphisms (SNPs) that were associated with human PCa risk \[[@R6]\]. Lu *et al.* demonstrated that SNPs associated with PCa risk were enriched in the androgen receptor (AR)-binding sites \[[@R7], [@R8]\]. These findings led to further functional studies to better understand PCa susceptibility.

The PI3K/AKT/mTOR signaling pathway is involved in many human malignancies, including PCa \[[@R9]--[@R11]\]. Nearly 25-70% of PCa cases show altered PI3K/AKT/mTOR signaling with higher prevalence in metastatic tumors. AKT is a proto-oncogene that is phosphorylated by a variety of extracellular stimuli and regulates multiple cellular processes involved in cell survival, growth, differentiation and proliferation. *G*enomic mutations of *PTEN* are reported for nearly 50% of primary PCa, especially in advanced disease \[[@R12]\]. Although AR is not a known physiological substrate of AKT, two AKT phosphorylation consensus sequences were identified in AR \[[@R13], [@R14]\]. It was postulated that some AKT substrate, eukaryotic initiation factor 4E-binding protein-1 (4EBP1) and ribosomal protein S6 kinase (P70) were associated with AR synthesis and resulted in PCa. Given these findings, the role of PI3K/AKT/mTOR pathway in PCa carcinogenesis needs to be established.

Previous pre-GWAS studies demonstrated that genetic variants in PI3K/AKT/mTOR pathway were associated with cancer risk, including PCa \[[@R15], [@R16]\]. However, they needed to be experimentally verified \[[@R7], [@R8]\]. In the present study, we analyzed if 17 SNPs in six pivotal genes (*K-ras*, *PTEN*, *AKT1*, *AKT2*, *mTOR*, and *Raptor*) of the mTOR pathway were associated with PCa susceptibility.

RESULTS {#s2}
=======

Characteristics of the subjects {#s2_1}
-------------------------------

Overall, there were no differences in distributions of age, smoking status, and BMI index between the 413 cases and 807 cancer-free controls (Table [1](#T1){ref-type="table"}). Among the case subjects, 321 (77.7%) Han and 92 (22.3%) Uygur case subjects were included. Of those, 221 (53.5%) cases had Gleason scores \<8 and the remaining 192 (46.5%) had Gleason scores ≥ 8.

###### Distribution of demographic and clinico-pathological characteristics of prostate cancer patients and cancer-free controls from Chinese men

  Variables             Cases no. (%)   Controls no. (%)   *P*^a^
  --------------------- --------------- ------------------ --------
  All subjects          413 (100)       807 (100)          
  Age, yr (Mean ± SD)   72 ±7.59        72 ±7.65           0.713
  ≤71                   171 (41.4)      343 (42.5)         
  \>71                  242 (58.6)      464 (57.5)         
  Ethnic group                                             0.179
   Han                  321 (77.7)      599 (74.2)         
   Uygur                92 (22.3)       208 (25.8)         
  BMI (kg/m^2^)                                            0.346
  ≤24                   217 (52.5)      401 (49.7)         
  \>24                  196 (47.5)      406 (50.3)         
  Smoking status                                           0.452
   Never                190 (46.0)      353 (43.7)         
   Ever                 223 (54.0)      454 (56.3)         
  Gleason score                                            
  \<8                   221 (53.5)                         
  \>=8                  192 (46.5)                         

SD: standard deviation; BMI: body mass index.

^a^Two-sided chi-square tests were used to calculate differences in the frequency distribution of genotypes between cases and controls.

Genotype distributions and their association with PCa risk {#s2_2}
----------------------------------------------------------

Among the 17 SNPs analyzed, three variants of two genes were associated with PCa risk, and another variant was associated with PCa risk by stratification analysis (Table [2](#T2){ref-type="table"}). The genotype distributions for *mTOR* rs17036508 C\>T (*P*=0.001) and rs2295080 G\>T (*P*=0.048) were different between cases and controls. The homozygote variant genotypes CC of *mTOR* rs17036508 C\>T were associated with PCa risk compared with genotypes TT (adjusted OR=3.73 (95% CI=1.75-7.94), *P=*0.001). Also, heterozygote genotypes GT of *mTOR* rs2295080 G\>T were protective compared to homozygote genotypes TT (adjusted OR=0.54 (95% CI= 0.32-0.91), *P* = 0.020). Furthermore, variants rs17036508 C\>T \[additive: adjusted OR=1.31 (95% CI =1.04-1.65), *P*=0.023; recessive: adjusted OR=3.69 (95% CI =1.74-7.83), *P*=0.001\] and rs2295080 G\>T \[dominant: adjusted OR=0.59 (95% CI = 0.36-0.96), *P*=0.035\] were also associated with PCa risk. For *Raptor* variants, heterozygote genotypes AG of polymorphism rs1468033 A\>G were associated with PCa risk compared to genotypes GG (adjusted OR=1.61 (95% CI =1.25-2.06), *P* \<0.001). We also found that rs1468033 A\>G was associated with PCa risk \[additive model: adjusted OR=1.42 (95% CI =1.17-1.73), *P*\<0.001; dominant model: adjusted OR=1.61 (95% CI = 1.26-2.05), *P*\<0.001\]. Further analysis of the combined genotypes of these three SNPs and *AKT2* rs7250897 C\>T showed enhanced PCa susceptibility with increasing numbers of putative high-risk genotypes (*P*~trend~\<0.001) (Table [3](#T3){ref-type="table"}).

###### Logistic regression analysis of associations between genotypes of PI3K/AKT/mTOR genes and prostate cancer risk in Chinese men

  Variables (HWE)^a^                 Cases (N=1004)   Controls (N=1051)   *P*^b^                Crude OR (95% CI)     *P*                   Adjusted OR (95% CI)^b^   *P*^c^
  ---------------------------------- ---------------- ------------------- --------------------- --------------------- --------------------- ------------------------- -------------
  ***mTOR* rs1034528 HWE:0.131**                                                                                                                                      
  GG                                 260(63.0)        507(62.8)                                 1.00                                        1.00                      
  CG                                 132(32.0)        274(34.0)                                 0.94(0.73-1.21)       0.632                 0.93(0.72-1.20)           0.563
  CC                                 21(5.1)          26(3.2)                                   1.58(0.87-2.85)       0.134                 1.59(0.87-2.90)           0.129
  Additive model                                      0.248               1.06(0.86-1.30)       0.612                 1.05(0.85-1.30)       0.656                     
  Dominant model                                      0.965               1.00(0.0.78-1.27)     0.965                 0.98(0.77-1.26)       0.895                     
  Recessive model                                     0.110               1.61(0.89-2.90)       0.113                 1.63(0.90-2.96)       0.105                     
  ***mTOR* rs17036508 HWE:0.451**                                                                                                                                     
  TT                                 299(72.4)        610(75.6)                                 1.00                                        1.00                      
  CT                                 94(22.8)         186(23.1)                                 1.03(0.78-1.37)       0.744                 1.05(0.79-1.40)           0.744
  CC                                 20(4.8)          11(1.4)                                   **3.71(1.76-7.84)**   **0.001**             **3.73(1.75-7.94)**       **0.001**
  Additive model                                      **0.001**           **1.29(1.03-1.63)**   **0.029**             **1.31(1.04-1.65)**   **0.023**                 
  Dominant model                                      0.226               1.18(0.90-1.55)       0.226                 1.20(0.92-1.58)       0.188                     
  Recessive model                                     **\<0.001**         **3.68(1.75-7.76)**   **0.001**             **3.69(1.74-7.83)**   **0.001**                 
  ***mTOR* rs12122605 HWE:0.533**                                                                                                                                     
  CC                                 249(60.3)        488(60.5)                                 1.00                                        1.00                      
  CT                                 142(34.4)        283(35.1)                                 0.98(0.76-1.27)       0.897                 0.98(0.76-1.26)           0.871
  TT                                 22(5.3)          36(4.5)                                   1.20(0.69-2.08)       0.522                 1.22(0.70-2.14)           0.479
  Additive model                                      0.791               1.03(0.84-1.26)       0.767                 1.03(0.84-1.27)       0.755                     
  Dominant model                                      0.951               1.01(0.79-1.28)       0.951                 1.01(0.79-1.29)       0.961                     
  Recessive model                                     0.501               1.21(0.70-2.08)       0.502                 1.23(0.71-2.14)       0.456                     
  ***mTOR* rs2295080 HWE:0.085**                                                                                                                                      
  TT                                 236(57.1)        454(56.3)                                 1.00                                        1.00                      
  GT                                 145(35.1)        316(39.2)                                 **0.53(0.32-0.89)**   **0.015**             **0.54(0.32-0.91)**       **0.020**
  GG                                 32(7.8)          37(4.6)                                   0.60(0.37-1.00)       0.050                 0.62(0.38-1.03)           0.064
  Additive model                                      **0.048**           0.94(0.77-1.14)       0.532                 0.95(0.78-1.16)       0.633                     
  Dominant model                                      **0.024**           **0.58(0.35-0.93)**   **0.025**             **0.59(0.36-0.96)**   **0.035**                 
  Recessive model                                     0.768               1.04(0.82-1.32)       0.768                 1.05(0.83-1.34)       0.676                     
  ***Raptor* rs1468033 HWE:0.278**                                                                                                                                    
  GG                                 165(34.0)        415(51.4)                                 1.00                                        1.00                      
  AG                                 217(52.5)        336(41.6)                                 **1.62(1.27-2.08)**   **\<0.001**           **1.61(1.25-2.06)**       **\<0.001**
  AA                                 31(7.5)          56(6.9)                                   1.39(0.87-2.24)       0.172                 1.61(0.99-2.62)           0.053
  Additive model                                      **0.001**           **1.37(1.13-1.65)**   **0.001**             **1.42(1.17-1.73)**   **\<0.001**               
  Dominant model                                      **\<0.001**         **1.59(1.25-2.02)**   **\<0.001**           **1.61(1.26-2.05)**   **\<0.001**               
  Recessive model                                     0.716               1.09(0.69-1.72)       0.716                 1.27(0.80-2.02)       0.317                     
  ***Raptor* rs2271610 HWE:0.558**                                                                                                                                    
  GG                                 243(58.8)        497(61.6)                                 1.00                                        1.00                      
  CG                                 140(33.9)        269(33.3)                                 1.06(0.82-1.37)       0.632                 1.07(0.82-1.38)           0.640
  CC                                 30 (7.3)         41(5.1)                                   1.50(0.91-2.46)       0.111                 1.64(0.99-2.70)           0.054
  Additive model                                      0.272               1.14(0.94-1.39)       0.177                 1.17(0.96-1.43)       0.117                     
  Dominant model                                      0.352               1.12(0.88-1.43)       0.353                 1.14(0.89-1.45)       0.299                     
  Recessive model                                     0.123               1.46(0.90-2.38)       0.125                 1.60(0.98-2.62)       0.062                     
  ***Raptor* rs2271612 HWE:0.138**                                                                                                                                    
  CC                                 185(44.8)        346(42.9)                                 1.00                                        1.00                      
  CT                                 182(44.1)        350(43.4)                                 0.97(0.76-1.25)       0.829                 0.98(0.76-1.26)           0.861
  TT                                 46(11.1)         111(13.8)                                 0.78(0.53-1.14)       0.197                 0.76(0.52-1.13)           0.174
  Additive model                                      0.424               0.91(0.76-1.08)       0.274                 0.90(0.76-1.08)       0.259                     
  Dominant model                                      0.522               0.93(0.73-1.18)       0.522                 0.93(0.73-1.18)       0.527                     
  Recessive model                                     0.197               0.79(0.55-1.13)       0.197                 0.77(0.53-1.12)       0.169                     
  ***Raptor* rs2292639 HWE:0.085**                                                                                                                                    
  CC                                 129(31.2)        235(29.1)                                 1.00                                        1.00                      
  AC                                 202(48.9)        394(48.8)                                 0.93(0.71-1.23)       0.625                 0.94(0.71-1.24)           0.645
  AA                                 82(19.9)         178(22.1)                                 0.84(0.60-1.18)       0.310                 0.86(0.61-1.21)           0.376
  Additive model                                      0.597               0.92(0.78-1.09)       0.315                 0.93(0.78-1.10)       0.378                     
  Dominant model                                      0.445               0.90(0.70-1.17)       0.445                 0.91(0.70-1.18)       0.490                     
  Recessive model                                     0.374               0.88(0.65-1.17)       0.374                 0.89(0.66-1.20)       0.450                     
  ***Raptor* rs3751932 HWE:0.541**                                                                                                                                    
  CC                                 290(20.2)        562(69.6)                                 1.00                                        1.00                      
  CT                                 112(27.1)        220(27.3)                                 0.99(0.76-1.29)       0.921                 0.99(0.0.76-1.30)         0.966
  TT                                 11(2.7)          25(3.1)                                   0.85(0.41-1.76)       0.666                 0.90(0.43-1.86)           0.773
  additive model                                      0.909               0.97(0.77-1.21)       0.753                 0.98(0.78-1.23)       0.848                     
  Dominant model                                      0.835               0.97(0.75-1.26)       0.836                 0.99(0.76-1.28)       0.907                     
  Recessive model                                     0.671               0.86(0.42-1.76)       0.672                 0.90(0.44-1.86)       0.775                     
  ***Raptor* rs3751934 HWE:0.885**                                                                                                                                    
  CC                                 136(32.9)        278(34.5)                                 1.00                                        1.00                      
  AC                                 200(48.4)        393(48.7)                                 1.04(0.80-1.36)       0.772                 1.02(0.78-1.33)           0.912
  AA                                 77 (18.6)        136 (16.9)                                1.16(0.82-1.64)       0.409                 1.12(0.79-1.59)           0.523
  Additive model                                      0.708               1.07(0.90-1.27)       0.433                 1.05(0.89-1.25)       0.563                     
  Dominant model                                      0.596               1.07(0.83-1.38)       0.596                 1.04(0.81-1.34)       0.748                     
  Recessive model                                     0.435               1.13(0.83-1.54)       0.436                 1.11(0.81-1.52)       0.509                     
  ***AKT1* rs2494750 HWE:0.165**                                                                                                                                      
  GG                                 128(31.0)        240(29.7)                                 1.00                                        1.00                      
  CG                                 196(47.5)        382(47.3)                                 0.96(0.73-1.27)       0.783                 0.97(0.74-1.28)           0.831
  CC                                 89(21.6)         185(22.9)                                 0.90(0.65-1.26)       0.542                 0.89(0.64-1.24)           0.484
  Additive model                                      0.830               0.95(0.81-1.12)       0.547                 0.94(0.80-1.11)       0.497                     
  Dominant model                                      0.652               0.94(0.73-1.22)       0.651                 0.94(0.73-1.22)       0.657                     
  Recessive model                                     0.586               0.92(0.69-1.23)       0.586                 0.90(0.68-1.21)       0.493                     
  ***AKT1* rs2494752 HWE:0.122**                                                                                                                                      
  AA                                 161(39.0)        305(37.8)                                 1.00                                        1.00                      
  AG                                 189(45.8)        365(45.2)                                 0.98(0.76-1.27)       0.884                 1.01(0.78-1.32)           0.921
  GG                                 63(15.3)         137(17.0)                                 0.87(0.61-1.24)       0.445                 0.87(0.61-1.25)           0.459
  Additive model                                      0.736               0.94(0.80-1.12)       0.496                 0.95(0.80-1.13)       0.558                     
  Dominant model                                      0.686               0.95(0.75-1.21)       0.685                 0.98(0.76-1.25)       0.837                     
  Recessive model                                     0.442               0.88(0.64-1.22)       0.442                 0.87(0.63-1.20)       0.396                     
  ***AKT2* rs2304186 HWE:0.036**                                                                                                                                      
  GG                                 120(29.1)        224(27.8)                                 1.00                                        1.00                      
  GT                                 209(50.6)        430(53.3)                                 0.91(0.69-1.20)       0.491                 0.91(0.69-1.20)           0.493
  TT                                 84(20.3)         153(19.0)                                 1.03(0.73-1.45)       0.890                 1.00(0.71-1.43)           0.981
  Additive model                                      0.669               1.00(0.84-1.19)       0.984                 0.99(0.83-1.18)       0.932                     
  Dominant model                                      0.633               0.94(0.72-1.22)       0.633                 0.93(0.72-1.22)       0.605                     
  Recessive model                                     0.564               1.09(0.81-1.47)       0.564                 1.07(0.79-1.44)       0.660                     
  ***AKT2* rs7250897 HWE:0.106**                                                                                                                                      
  TT                                 181(43.8)        397(49.2)                                 1.00                                        1.00                      
  CT                                 190(46.0)        324(40.2)                                 1.29(1.00-1.65)       0.049                 1.29(1.00-1.67)           0.047
  CC                                 42(10.2)         86(10.7)                                  1.07(0.71-1.61)       0.742                 1.11(0.73-1.67)           0.631
  Additive model                                      0.139               1.12(0.94-1.33)       0.226                 1.13(0.94-1.35)       0.183                     
  Dominant model                                      0.633               1.24(0.98-1.58)       0.076                 1.25(0.99-1.60)       0.066                     
  Recessive model                                     0.564               0.95(0.64-1.40)       0.794                 0.98(0.66-1.45)       0.909                     
  ***AKT2* rs7254617 HWE:0.120**                                                                                                                                      
  GG                                 298(72.2)        581(72.0)                                 1.00                                        1.00                      
  AG                                 102(24.7)        214(26.5)                                 0.93(0.71-1.22)       0.600                 0.93(0.71-1.23)           0.619
  AA                                 13(3.2)          12(1.5)                                   2.11(0.95-4.69)       0.066                 2.00(0.90-4.47)           0.091
  Additive model                                      0.134               1.06(0.84-1.34)       0.621                 1.06(0.83-1.34)       0.654                     
  Dominant model                                      0.953               0.99(0.76-1.29)       0.953                 0.99(0.76-1.29)       0.949                     
  Recessive model                                     0.053               2.15(0.97-4.76)       0.058                 2.04(0.91-4.54)       0.082                     
  ***PTEN* rs701848 HWE:0.212**                                                                                                                                       
  TT                                 134(32.5)        245(30.4)                                 1.00                                        1.00                      
  CT                                 210(50.9)        415(51.4)                                 0.93(0.71-1.21)       0.570                 0.93(0.71-1.22)           0.588
  CC                                 69(16.7)         147(18.2)                                 0.86(0.60-1.22)       0.399                 0.87(0.61-1.25)           0.460
  Additive model                                      0.687               0.93(0.78-1.10)       0.386                 0.93(0.78-1.11)       0.442                     
  Dominant model                                      0.456               0.91(0.70-1.17)       0.456                 0.91(0.71-1.18)       0.492                     
  Recessive model                                     0.514               0.90(0.66-1.23)       0.514                 0.92(0.67-1.26)       0.584                     
  ***K-ras* rs7312175 HWE:0.127**                                                                                                                                     
  GG                                 294(71.2)        592(73.4)                                 1.00                                        1.00                      
  AG                                 210(25.9)        192(23.8)                                 1.12(0.85-1.48)       0.411                 1.18(0.90-1.56)           0.238
  AA                                 12(2.9)          23(2.9)                                   1.05(0.52-2.14)       0.892                 1.07(0.52-2.19)           0.860
  Additive model                                      0.712               1.09(0.87-1.36)       0.478                 1.13(0.90-1.42)       0.314                     
  Dominant model                                      0.421               1.12(0.86-1.45)       0.421                 1.17(0.90-1.53)       0.250                     
  Recessive model                                     0.956               1.02(0.50-2.07)       0.956                 1.02(0.50-2.09)       0.952                     

OR: odds ratio; CI: confidence interval.

^a^Hard-Wenberg equilibrium test for controls.

^b^Two-sided Chi-square tests were used to calculate differences in the frequency distribution of genotypes between cases and controls.

^c^Adjusted for age, smoking, and BMI status in logistic regress models.

The results were in bold, if the 95% CI excluded 1 or *P*\<0.05.

###### Combined effects of risk genotypes of of PI3K/AKT/mTOR genes by dominant genetic models

  -------------------------------------------------------------------------------------------------------------------------------------
  Variables genotypes   Cases\       Controls\    *P*^a^        Crude OR\             *P*           Adjusted OR\          *P*^b^
                        (N=413)      (N=807)                    (95% CI)                            (95% CI)^a^           
  --------------------- ------------ ------------ ------------- --------------------- ------------- --------------------- -------------
  0                     33(8.0)      142(17.6)    **\<0.001**   1.00                                1.00                  

  1                     114(27.6)    251(31.1)                  **1.95(1.26-3.03)**   **0.003**     **2.04(1.31-3.18)**   **0.002**

  2                     178 (43.1)   226 (28.0)                 **3.39(2.21-5.19)**   **\<0.001**   **3.50(2.27-5.38)**   **\<0.001**

  3                     86 (20.8)    188(23.3)                  **1.97(1.25-3.11)**   **0.004**     **2.07(1.30-3.28)**   **0.002**

  4                     2(0.5)       0(0)                       **------**                          **------**            

                                                                                                    *P*~trend~\<0.001     

  0                     33(8.0)      142(17.6)    **\<0.001**   1.00                                1.00                  

  ≥1                    380(92.0)    665(82.4)                  **2.46(1.65-3.67)**   **\<0.001**   **2.56(1.71-3.84)**   **\<0.001**
  -------------------------------------------------------------------------------------------------------------------------------------

^a^Chi-square test was used to calculate the genotype frequency distributions.

^b^Obtained under dominant models in logistic regression analyses with adjustment for age, smoking status and BMI.

The results were in bold, if the 95% CI excluded 1 or *P*\<0.05.

Stratification analysis of PCa risk associated with significant variants {#s2_3}
------------------------------------------------------------------------

The *mTOR* rs17036508 CT/CC genotypes correlated with increased PCa risk particularly in subgroup of age ≤71 (dominant model: adjusted OR =1.81 (95% CI =1.19-2.77), *P* = 0.006). Further, the *mTOR* rs17036508 CC genotypes were associated with increased PCa risk by recessive genetic model for subgroups of age ≤71(adjusted OR=4.75 (95%CI =1.78-12.71), *P* = 0.002), age \>71 (adjusted OR=4.88 (95%CI =1.65-14.38), *P* = 0.004), BMI ≤24 kg/m^2^ (adjusted OR=3.20 (95%CI =1.2-8.53), *P* = 0.02), BMI \>24 kg/m^2^ (adjusted OR=8.11 (95%CI =2.62-25.11), *P*\< 0.001), ever smokers (adjusted OR=6.39 (95%CI =2.46-16.6), *P*\< 0.001), and Uygur population (adjusted OR=5.09 (95%CI =2.2-11.78), *P*\< 0.001). On the contrary, the *mTOR* rs2295080 GT/GG genotypes were associated with decreased PCa risk by a dominant genetic model in BMI \>24 kg/m^2^ and ever smokers subgroups. However, the *mTOR* rs2295080 GG genotypes were associated with PCa risk among age subgroups according to the recessive genetic model. For *Raptor* rs1468033 A\>G, AG/AA genotypes were associated with increased PCa risk by the dominant genetic model, particularly in subgroups of age \>71(adjusted OR=1.81 (95%CI =1.31-2.48), *P* = 0.003), BMI \>24kg/m^2^ (adjusted OR=2.02 (95%CI =1.42-2.87), *P*\< 0.001), never smokers (adjusted OR=1.61 (95%CI =1.21-2.30), *P* = 0.009), ever smokers (adjusted OR=1.58 (95%CI =1.13-2.19), *P* = 0.068), and Uygur population (adjusted OR=1.66 (95%CI =1.26-2.20), *P*\< 0.001). Furthermore, increased PCa risk was observed by recessive genetic model for the BMI \>24 kg/m^2^ subgroup (adjusted OR=5.13 (95% CI=1.94-13.59), *P* = 0.001). Increased PCa risk was observed for *AKT2* rs7250897 C\>T by the dominant genetic model, particularly in subgroups of age \>71(adjusted OR=1.83 (95%CI =1.33-2.52), *P* = 0.002) and BMI \>24kg/m^2^ (adjusted OR=1.58 (95%CI =1.12-2.24), *P* = 0.010). However, further homogeneity tests showed no difference in risk estimates between subgroups for most strata except age group by *mTOR* rs17036508 CT/CC genotypes (*P*=0.032), *mTOR* rs2295080 GG genotypes (*P*=0.002), *AKT2* rs7250897 CT/CC genotypes (*P*\<0.001) and BMI group by *Raptor* rs1468033 AA genotypes (*P*\<0.001). The details are shown in Table [4](#T4){ref-type="table"}.

###### Stratification analysis for associations between PI3K/AKT/mTOR variants and prostate cancer risk in Chinese men

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables          *mTOR*\                Adjusted         *P*^a^             *P*^hom^       *mTOR*\                Adjusted         *P*^a^       *P*^hom^          *Raptor*\              Adjusted         *P*^a^       *P*^hom^       *AKT2*\                Adjusted         *P*^a^        *P*^hom^                                                 
                     rs17036508                                                                rs2295080                                                              rs1468033                                                           rs7250897                                                                                                      
  ------------------ ---------------------- ---------------- ------------------ -------------- ---------------------- ---------------- ------------ ----------------- ---------------------- ---------------- ------------ -------------- ---------------------- ---------------- ------------- -------------- --------- ----------------- ------------- -------------
  Age, yr (median)                                                                                                                                                                                                                                                                                                                                       

  ≤71                53/69                  118/274          **1.81**\          **0.006**      **0.032**              158/329          13/14        0.54\             0.127                  0.741            102/180      69/163         1.38(0.94-2.01)        0.097            0.227         82/191         89/152    0.76\             0.145         **\<0.001**
                                                             **(1.19-2.77)**                                                                        (0.25-1.19)                                                                                                                                                          (0.52-1.10)                     

  \>71               66/128                 176/336          1.02\              0.926                                 223/441          19/23        0.60\             0.120                                   146/212      96/252         **1.81(1.31-2.48)**    **\<0.001**                    150/219        92/245    **1.83**\         **\<0.001**   
                                                             (0.72-1.45)                                                                            (0.32-1.14)                                                                                                                                                          **(1.33-2.52)**                 

  BMI, kg/m^2^                                                                                                                                                                                                                                                                                                                                           

  ≤24                63/105                 154/296          1.23\              0.280          0.536                  203/382          14/19        0.70\             0.339                  0.366            123/203      94/198         1.25(0.89-1.75)        0.196            0.062         114/212        103/189   0.99\             0.959         0.051
                                                             (0.85-1.79)                                                                            (0.34-1.45)                                                                                                                                                          (0.71-1.39)                     

  \>24               56/92                  140/314          1.36\              0.117                                 178/388          18/18        **0.43**\         **0.016**                               125/189      71/217         **2.02(1.42-2.87)**    **\<0.001**                    118/198        78/208    **1.58**\         **0.010**     
                                                             (0.93-1.01)                                                                            **(0.22-0.86)**                                                                                                                                                      **(1.12-2.24)**                 

  Smoking status                                                                                                                                                                                                                                                                                                                                         

  Never              50/80                  140/273          1.22\              0.341          0.835                  179/335          11/18        0.87\             0.728                  0.152            113/169      77/184         **1.61(1.12-2.30)**    **0.009**        0.982         102/171        88/182    1.24\             0.231         0.938
                                                             (0.81-1.84)                                                                            (0.40-1.89)                                                                                                                                                          (0.87-1.77)                     

  Ever               69/117                 154/337          1.34\              0.109                                 202/435          21/19        **0.42**\         **0.008**                               135/223      88/231         **1.58(1.13-2.19)**    **0.007**                      130/239        93/215    1.24\             0.206         
                                                             (0.94-1.92)                                                                            **(0.22-0.80)**                                                                                                                                                      (0.89-1.72)                     

  Ethnic group                                                                                                                                                                                                                                                                                                                                           

  Han                24/52                  68/156           1.12\              0.703          0.504                  82/194           10/14        0.61\             0.266                  0.871            51/96        41/112         1.44(0.87-2.36)        0.155            0.693         51/94          41/114    1.52\             0.099         0.358
                                                             (0.63-1.97)                                                                            (0.26-1.45)                                                                                                                                                          (0.92-2.51)                     

  Uygur              95/145                 226/454          1.33\              0.068                                 299/576          22/23        0.56\             0.057                                   197/296      124/303        **1.66(1.26-2.20)**    **\<0.001**                    181/316        140/283   1.18\             0.237         
                                                             (0.98-1.81)                                                                            (0.30-1.02)                                                                                                                                                          (0.90-1.56)                     

  **Variables**      ***mTOR***\            **Adjusted**     ***P***^a^         ***P***^hom^   ***mTOR***\            **Adjusted**     ***P***^a^   ***P***^hom^      ***Raptor***\          **Adjusted**     ***P***^a^   ***P***^hom^   ***AKT2***\            **Adjusted**     ***P***^a^    ***P***^hom^                                             
                     **rs17036508**                                                            **rs2295080**                                                          **rs1468033**                                                       **rs7250897**                                                                                                  

                     **(Cases/Controls)**   **OR**\                                            **(Cases/Controls)**   **OR**\                                         **(Cases/Controls)**   **OR**\                                      **(Cases/Controls)**   **OR**\                                                                                 
                                            **(95%CI)**^a^                                                            **(95%CI)**^a^                                                         **(95%CI)**^a^                                                      **(95%CI)**^a^                                                                          

  **by REM**         CC                     TT+CT                                                                     GG               TT+GT                                                                  AA           GG+AG                                                                CC             TT+CT                                     

  Age, yr (median)                                                                                                                                                                                                                                                                                                                                       

  ≤71                157/337                14/6             **4.75**\          **0.002**      0.854                  81/128           90/215       **0.67**\         **0.035**              **0.002**        158/318      13/25          1.19(0.54-2.42)        0.635            0.882         154/303        17/40     0.89\             0.710         0.577
                                                             **(1.78-12.71)**                                                                       **(0.46-0.97)**                                                                                                                                                      (0.49-1.63)                     

  \>71               231/459                11/5             **4.88**\          **0.004**                             96/225           146/239      **1.46**\         **0.021**                               224/433      18/31          1.34(0.72-2.49)        0.351                          217/418        25/46     1.05\             0.858         
                                                             **(1.65-14.38)**                                                                       **(1.06-2.00)**                                                                                                                                                      (0.62-1.76)                     

  BMI, kg/m^2^                                                                                                                                                                                                                                                                                                                                           

  ≤24                206/394                11/7             **3.20**\          **0.020**      0.210                  90/176           127/225      1.09\             0.622                  0.592            200/351      17/50          0.66(0.37-1.18)        0.163            **\<0.001**   193/352        24/49     0.89\             0.674         0.943
                                                             **(1.20-8.53)**                                                                        (0.78-1.53)                                                                                                                                                          (0.53-1.51)                     

  \>24               182/402                14/4             **8.11**\          **\<0.001**                           87/177           109/229      0.97\             0.859                                   182/400      14/6           **5.13(1.94-13.6)**    **0.001**                      178/369        18/37     0.99\             0.985         
                                                             **(2.62-25.11)**                                                                       (0.69-1.37)                                                                                                                                                          (0.55-1.80)                     

  Smoking status                                                                                                                                                                                                                                                                                                                                         

  Never              182/348                8/5              3.01\              0.057          0.352                  81/157           109/196      1.08\             0.663                  0.775            180/333      10/20          0.94(0.43-2.07)        0.884            0.588         170/319        20/34     1.11\             0.729         0.507
                                                             (0.97-9.34)                                                                            (0.76-1.55)                                                                                                                                                          (0.62-1.99)                     

  Ever               206/448                17/6             **6.39**\          **\<0.001**                           96/196           127/258      1.00\             0.987                                   202/418      21/36          1.45(0.82-2.59)        0.206                          201/402        22/52     0.86\             0.589         
                                                             **(2.46-16.60)**                                                                       (0.72-1.39)                                                                                                                                                          (0.51-1.47)                     

  Ethnic group                                                                                                                                                                                                                                                                                                                                           

  Han                87/205                 5/3              3.90\              0.069          0.794                  37/89            55/119       1.08\             0.778                  0.764            85/191       7/17           1.10(0.43-2.80)        0.848            0.675         84/188         8/20      0.95\             0.902         0.893
                                                             (0.90-16.98)                                                                           (0.65-1.78)                                                                                                                                                          (0.40-2.26)                     

  Uygur              301/591                20/8             **5.09**\          **\<0.001**                           140/264          181/335      1.05\             0.747                                   297/560      24/39          1.34(0.78-2.30)        0.284                          287/533        34/66     0.99\             0.946         
                                                             **(2.20-11.78)**                                                                       (0.79-1.38)                                                                                                                                                          (0.63-1.53)                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI: body mass index. ^a^ Obtained under dominant models in logistic regression analyses with adjustment for age, smoking status and BMI. ^b,c^ According to the current WHO recommendations.

*P*^hom^*P* value for homogeneiy test. DOM: dominant genetic model; REM: recessive genetic model.

The results were in bold, if *P*\<0.05.

Association of high-order interactions with PCa risk {#s2_4}
----------------------------------------------------

We performed the multifactor dimensionality reduction (MDR) analysis by including the genotypes of four significant genetic factors (*mTOR* rs17036508 CC and rs2295080 TT, *Raptor* rs1468033 AG/AA, and *AKT2* rs7250897 TT/CT) and four environmental risk factors (age at diagnosis, smoking status, race, and BMI). Among all 8 factors, the *Raptor* rs1468033 A\>G variant was the best one-factor model. Likewise, interactions between *mTOR* rs17036508 CC, rs2295080 TT and *Raptor* rs1468033 AG/AA represented the best three-factor model. Age was the most promising environmental risk factor associated with the four genetic factors. The details are presented in Table [5](#T5){ref-type="table"}. Subsequent hierarchical cluster analysis placed BMI and smoking status, race and rs17036508 C\>T, rs2295080 G\>T and rs1468033 A\>G, age and rs7250897 C\>T on the same branch. This suggested that interactions in this eight-locus model may modulate PCa risk (data not shown).

###### MDR analysis for the risk of prostate cancer prediction in an Chinese population

  ---------------------------------------------------------------------------------------------------------------------------
  Best interaction models                                                Cross-validation   Average\           *P*-value^a^
                                                                                            prediction error   
  ---------------------------------------------------------------------- ------------------ ------------------ --------------
  rs1468033                                                              100/100            0.4566             0.0001

  rs2295080 rs1468033                                                    100/100            0.3451             p \< 0.0001

  rs17036508 rs2295080 rs1468033                                         **100/100**        **0.3434**         p \< 0.0001

  age rs17036508 rs2295080 rs1468033                                     99/100             0.4066             p \< 0.0001

  age rs17036508 rs2295080 rs1468033 rs7250897                           78/100             0.4254             p \< 0.0001

  BMI smoking_status race rs17036508 rs2295080 rs1468033                 45/100             0.4467             p \< 0.0001

  smoking_status age race rs17036508 rs2295080 rs1468033 rs7250897       61/100             0.4022             p \< 0.0001

  BMI smoking_status age race rs17036508 rs2295080 rs1468033 rs7250897   100/100            0.5066             p \< 0.0001
  ---------------------------------------------------------------------------------------------------------------------------

MDR: multifactor dimensionality reduction.

The best model with maximum cross-validation consistency and minimum prediction error rate was in bold.

^a^*P*-value for 1000-fold permutation test.

Finally, we analyzed the false-positive report probability (FPRP) values at variant prior probability levels for all positive findings (Table [6](#T6){ref-type="table"}). Some higher statistical power (81.7%-89.6%) was observed under the assumption of prior probability of 0.25. However, some significant findings were still noteworthy at prior probability of 0.01 in spite of the lower statistical power (range from 5% to 45%). Some findings with greater FPRP values need further validation in larger studies.

###### False-positive report probability values for associations between the PCa risk and the frequency of Genotypes of PI3K/AKT/mTOR variants

  Genotype                              Crude OR (95%CI)   *P*^a^     Statistical power^b^   Prior probability                                   
  ------------------------------------- ------------------ ---------- ---------------------- ------------------- ----------- ----------- ------- -------
  **All patients**                                                                                                                               
  *mTOR* rs17036508 CC vs TT            3.71(1.76-7.84)    0.0006     0.008                  **0.18**            0.397       0.879       0.986   0.999
  *mTOR* rs17036508 CC vs CT/TT         3.68(1.74-7.76)    0.0003     0.005                  **0.15**            0.345       0.853       0.983   0.998
  *mTOR* rs2295080 GT vs TT             0.53(0.32-0.89)    0.0484     0.862                  **0.144**           0.336       0.848       0.982   0.998
  *mTOR* rs2295080 GG/GT vs TT          0.57(0.35-0.93)    0.0236     0.829                  **0.079**           0.204       0.738       0.966   0.997
  *raptor* rs1468033 AG vs GG           1.62(1.27-2.08)    0.0006     0.415                  **0.004**           **0.013**   **0.125**   0.591   0.935
  *raptor* rs1468033 AA/AG vs GG        1.59(1.25-2.02)    0.0001     0.284                  **0.001**           **0.003**   **0.034**   0.26    0.779
  ***mTOR* rs17036508**                                                                                                                          
   Age≤71 yrs, CT/CC vs TT              1.69(1.11-2.57)    0.0143     0.363                  **0.106**           0.262       0.796       0.975   0.997
   Age≤71 yrs, CC vs CT/CC              4.24(1.56-11.50)   0.0022     0.61                   **0.011**           **0.031**   0.263       0.783   0.973
   Age\>71 yrs,CC vs CT/CC              3.14(1.02-9.69)    0.0366     0.876                  **0.111**           0.273       0.805       0.977   0.998
   BMI\<=24,CC vs CT/CC                 2.72(1.02-7.24)    0.0378     0.896                  **0.112**           0.275       0.807       0.977   0.998
   BMI\>24,CC vs CT/CC                  5.40(1.67-17.45)   0.0017     0.571                  **0.009**           **0.026**   0.228       0.748   0.968
   Ever smoking, CC vs CT/TT            4.62(1.73-12.33)   0.0008     0.457                  **0.005**           **0.016**   **0.148**   0.636   0.946
   uygur, CC vs CT/TT                   4.39(1.89-10.21)   0.0002     0.160                  **0.004**           **0.011**   **0.110**   0.555   0.926
  ***mTOR* rs2295080**                                                                                                                           
   BMI\>24, GG/GT vs TT                 0.46(0.23-0.90)    0.0213     0.833                  **0.071**           **0.187**   0.717       0.962   0.996
   Ever smoking, GG/GT vs TT            0.42(0.22-0.80)    0.0067     0.722                  **0.027**           **0.077**   0.479       0.903   0.989
   Age≤71 yrs, GG vs GT/TT              0.66(0.46-0.96)    0.0288     0.504                  **0.146**           0.34        0.85        0.983   0.998
   Age\>71 yrs, GG vs GT/TT             1.43(1.04-1.96)    0.0255     0.817                  **0.086**           0.219       0.755       0.969   0.997
  ***Raptor* rs1468033**                                                                                                                         
   Age\>71 yrs, AA/AG vs GG             1.81(1.32-2.48)    0.0002     0.276                  **0.002**           **0.006**   **0.067**   0.42    0.879
   BMI\>24, AA/AG vs GG                 2.02(1.42-2.87)    \<0.0001   0.198                  **0.002**           **0.005**   **0.048**   0.335   0.835
   Ever smoking, AA/AG vs GG            1.59(1.15-2.20)    0.0051     0.547                  **0.027**           **0.077**   0.48        0.903   0.989
   Never smoking, AA/AG vs GG           1.60(1.12-2.28)    0.0099     0.712                  **0.040**           **0.111**   0.579       0.933   0.993
   Uygur group, AA/AG vs GG             1.63(1.23-2.14)    0.0005     0.433                  **0.003**           **0.010**   **0.103**   0.536   0.920
   BMI\>24, AA vs AG/GG                 5.13(1.94-13.56)   0.0003     0.382                  **0.002**           **0.007**   **0.072**   0.440   0.887
  ***AKT2* rs7250897**                                                                                                                           
   Age\>71 yrs, CT/CC vs TT             1.82(1.33-2.51)    0.0002     0.284                  **0.002**           **0.006**   **0.065**   0.413   0.876
   BMI\>24, CT/CC vs TT                 1.60(1.12-2.25)    0.0085     0.662                  **0.037**           **0.104**   0.56        0.928   0.992
  **Combined effect (risk genotype)**                                                                                                            
  **0 vs \>=1**                         2.46(1.65-3.67)    \<0.0001   0.050                  **0.006**           **0.018**   **0.165**   0.666   0.952

OR: odds ratio; CI: confidence interval; BMI: body mass index.

^a^Chi-square test was used to calculate the genotype frequency distributions.

^b^Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table.

The results in false-positive report probability analysis were in bold, if the prior probability \< 0.2.

DISCUSSION {#s3}
==========

In the current single institution based case-control study, functional SNPs of six pivotal genes of PI3K/AKT/mTOR pathway were associated with PCa risk. Briefly, the *mTOR* rs17036508 CC, *mTOR* rs2295080 GG/GT, *Raptor* rs1468033 AG/AA, and *AKT* rs7250897 TT/CT genotypes were associated with PCa risk, especially in age, BMI, smoker-status, and ethnic subgroups. To the best of our knowledge, this is the first post-GWAS study analyzing associations of these six pivotal genes of PI3K/AKT/mTOR pathway with PCa risk.

The *mTOR* gene is a critical cellular protein with more than 2651 SNPs reported across the whole region \[[@R17]\]. However, only few SNPs have been associated with PCa susceptibility. Two studies showed that *mTOR* rs2295080 GT/GG genotypes protected against PCa risk in Han Chinese populations \[[@R18], [@R19]\]. These findings were consistent with mixed Chinese populations in the present study, but not in separate ethnic subgroups (Han or Uygur). The effects of the *mTOR* rs2295080 GT/GG genotypes were also observed in esophageal squamous cell carcinoma, gastric carcinoma, and renal cell carcinoma \[[@R20]--[@R22]\]. *In vitro* and *in vivo* studies suggested that *mTOR* rs2295080 T allele probably increased the affinity of special transcription factors to this promoter region and contributed to enhanced mTOR activity \[[@R20]\]. Variant *mTOR* rs2295080 was linked to eight potential functional variants of *mTOR* with higher linkage disequilibrium (LD) coefficient \>0.8, including rs1064261, rs1074078, rs1135172, rs1883965, rs4845860, rs6540965, and rs6671083. Among these, the variant rs1064261 probably interrupted the exonic splicing enhancer or silencer motif and correlated with neuroendocrine tumors \[[@R23]\], gastric cancer \[[@R24]\], and esophageal squamous cell carcinoma \[[@R25]\]. Similarly, as a probable transcription factor binding site of *mTOR*, variant rs1883965 was associated with esophageal carcinoma, gastric cancer, and hepatocellular carcinoma \[[@R26]\]. Additionally, it was predicted that variant rs17036508 of *mTOR* was located within a miRNA binding site and an exonic splicing enhancer or silencer motif, thereby affecting pre-RNA splicing. The association between rs17036508 and PCa was also observed previously \[[@R19]\]. In the present study, we found that homozygote variant carriers of rs17036508 were more likely to develop cancer compared to homozygote wild carriers. In theory, polymorphism rs17036508 located in 3'-UTR of angiopoietin-like 7 gene (*ANGPTL7)*, resulting in upregulation of ANGPTL7 by hypoxia in cancer cells, which exerts a pro-angiogenesis effect \[[@R27]\]. Taken together, it is biologically plausible that these two polymorphisms might mediate tumor formation by regulating the expression of *mTOR* and *ANGPTL7* simultaneously.

The *Raptor* gene, located in 17q25.3 with 34 exons, regulates responses to nutrient and insulin levels \[[@R28]\]. The Raptor protein forms a stoichiometric complex with the mTOR kinase, and is associated with 4EBP1and P70. Previous *in vitro* and *in vivo* studies have shown that Raptor acts as a scaffold protein that regulates mTOR-dependent signaling \[[@R29]\]. One of the mechanisms involves changes in phosphorylation status of Raptor. However, the mechanism through which Raptor regulates these processes is only beginning to be established. In a recent study, *Raptor* gene polymorphisms were associated with increased risk for bladder cancer; physical activity, energy balance and genetic variants in the mTOR pathway co-coordinately influenced bladder cancer risk \[[@R30]\]. In this study, variant *Raptor* rs1468033 was associated with PCa risk, particularly in subgroups of age, BMI, and smoking status, similar to previous findings. *Silico* analysis indicated that rs1468033 was found with several potential functional polymorphisms of *Raptor* gene, including rs2292639, rs499609, rs6565500, and rs9899178. Among these, rs2292639, rs4999609, and rs6565500 were predicted as transfactor binding sites, whereas rs9899178 was predicted as splicing site. It is plausible that these variants modulate the expression of *Raptor* gene, and affect mTOR activity.

Although mTOR activity was previously implicated in promoting PCa cell invasion, the role of *AKT2* was not known. The different *AKT* isoforms (*AKT1*, *AKT2*, and *AKT3*) play contradictory regulatory roles; for example, AKT1 activation inhibits cell migration whereas AKT2 promotes it \[[@R31], [@R32]\]. Many studies have indicated that AKT2 is a more promising therapeutic target than PI3K due to its involvement in normal cellular processes. AKT2 downregulated GSK3b, which modulates cell migration \[[@R33]\]. Additionally, AKT negatively regulates Mdm2 expression during abnormal stress and promotes tumorigenesis \[[@R34]\]. Recently, Chen *et al.* reported that AKT2 rs7254617 increased prostate cancer risk \[[@R18]\]. Also, a Caucasian study showed that AKT2 variant rs3730050 was associated with poor prognosis of bladder cancer patients. Therefore, AKT isoforms are cancer susceptibility genes. In this study, *AKT2* rs7250897 was associated with increased PCa risk by a dominant genetic model in subgroups of age \>71and BMI \>24kg/m^2^, indicating that rs7250897 altered *AKT2* expression, which subsequently affected synthesis of adipose-related proteins. Since the three variants were far from each other, we postulated that they were associated with carcinogenesis by different mechanisms. These findings need to be further validated.

There were few limitations in the present study that need to be addressed. First, the limited sample size in our study may have decreased detection of weaker genetic effects in carcinogenesis. Second, information regarding predisposition to PCa was not collected for the analysis and might confuse the stratified positive associations. Third, the case-control study may have inherent selection and information biases. Because of insufficient medical records, we could not perform correlative analyses between stages of PCa and variants of AKT pathway that may have provided more information in PCa carcinogenesis. Moreover, further *in vitro* and *in vivo* experiments are necessary to unravel molecular mechanisms for the genetic associations that we have postulated in this study.

In summary, we showed that variants of PI3K/AKT/mTOR signal pathway genes may associate with PCa risk. The combined genotypes of these variants enhanced PCa risk with increasing numbers of putative high-risk genotypes. Moreover, the three-factor model (rs17036508, rs2295080, rs1468033) was the best model to predict PCa risk. In conclusion, our study postulated that the genetic variants may alter the expression and activity of *mTOR* leading to PCa susceptibility.

MATERIALS AND METHODS {#s4}
=====================

Patients and controls {#s4_1}
---------------------

We recruited 413 newly diagnosed PCa cases and 807 frequency-matched cancer-free controls from genetically unrelated Chinese Han and Uygur participants in Xinjiang province between January 2003 and January 2015. The cases were histopathologically confirmed as primary prostate adenocarcinoma at the First Affiliated Hospital of Xinjiang medical University (XJMU). Pathological grades of the PCa were determined by Gleason scores from the radical prostatectomy specimens according to the latest WHO criteria \[[@R35]\]. The recruited healthy controls were extracted from males who had health check-up in the First Affiliated Hospital of XJMU during the same period. Individuals with serum PSA \>4ng/ml were excluded from the control group.

All subjects were interviewed with a written informed consent. Response rate was 92% and 90% for cases and controls, respectively. The experimental and research protocols were approved by the Institutional Review Board of XJMU.

Selection of single nucleotide polymorphisms {#s4_2}
--------------------------------------------

For the six pivotal genes in PI3K/AKT/mTOR pathway, selection strategy for the potentially functional SNPs was based on the NCBI dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP>) and SNPinfo web server (<http://snpinfo.niehs.nih.gov/snpfunc.htm>). The criteria were: 1) minor allele frequency (MAF) was at least 5% in Chinese populations; 2) SNPs were potentially functional according to SNPinfo prediction platform. Ultimately, 17 potentially functional variants were selected involving *mTOR* (rs1034528 C\>G, rs1703658 C\>T, rs12122605 T\>C, and rs2295080 G\>T), *Raptor* (rs2271610 C\>G, rs2271612 T\>C, rs2292639 A\>C, rs3751932 T\>C, rs3751934 A\>C), *AKT1* (rs2494750 C\>G, rs2494752 G\>A), *AKT2* (rs2304186 T\>G, rs7250897 C\>T, rs7254617 A\>G), *PTEN* (rs701848 C\>T), and *K-ras* (rs7312175 A\>G) based on the bioinformatics analysis performed with HaploView software 4.2. All these SNPs were genotyped by the TaqMan real-time PCR method as described previously \[[@R36]\]. In this study, the quality control strategy was established as follows: (1) the discrepancy rate in all positive controls was less than 0.1%; (2) the results with \>95% call rates and 100% concordance for duplicated specimens were favorable for further analysis.

Statistical analysis {#s4_3}
--------------------

We performed the Pearson's χ^2^-test for the differences in selected variables between cases and controls. Crude and adjusted ORs and their 95% CIs were computed from both univariate and multivariate unconditional logistic regression models. We further evaluated the stratified associations based on the significant genetic models accompanied by the homogeneity Q-tests for the strata. For all the significant findings, we calculated FPRP with the assumption of different prior probabilities to detect any possible false positive associations. Only FPRP values\<0.2 were considered noteworthy \[[@R37]\]. All statistical analyses were performed with SAS 9.1 statistical software (SAS, Cary, NC, USA) unless stated otherwise. All *P* values were two-sided with a significance level of *P*\<0.05.

The multifactor dimensionality reduction (MDR) analysis was conducted by the MDR V2.0 beta 8.2 software (<http://www.multifactordimensionalityreduction.org/>) to identify the best *n*-factor interaction model \[[@R38]\]. We further performed the interaction dendrograms and graphs for risk loci of this study, and the color of branches and lines referred to the type of interaction, with green-to-yellow-to-red indicating weak-to-strong interactions.
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